Considering the pathological types of lung cancers, EGFR mutations were mainly found in adenocarcinomas compared to non-adenocarcinomas (61.12% vs 17.07%, p < 0.0001), while mutations in TP53 were mainly found in non-adenocarcinomas compared to adenocarcinomas (53.70% vs 38.60%, p < 0.05). This evidence concerns the gene TP53 and lung carcinoma.